Tag Archives: NASDAQ:LXRX

Needham Remains a Hold on Lexicon Pharmaceuticals (LXRX)

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) yesterday. The company’s shares closed yesterday at $5.97. Carr noted: “Lexicon reported 1Q19 U.S. Xermelo sales of $6.7M, below our $8.0M est. Mgmt reiterated 2019

Needham Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)

Needham analyst Alan Carr maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed on Friday at $6.20. Carr wrote: “Lexicon and collaborator Sanofi announced Friday that the FDA issued a Complete Response Letter

Lexicon Pharmaceuticals (LXRX) Receives a Hold from Cowen & Co.

In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares closed yesterday at $8.49, close to its 52-week low of $7.42. According to TipRanks.com, Shibutani is a

Stifel Nicolaus Reiterates a Buy Rating on Lexicon Pharmaceuticals

In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $23. The company’s shares closed yesterday at $11.43. According to TipRanks.com, Willey is a 5-star analyst

Needham Keeps a Hold Rating on Lexicon Pharmaceuticals

In a report released today, Alan Carr from Needham maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares opened today at $12.58. Carr wrote: “Lexicon reported 2Q18 U.S. Xermelo sales of $6.0M, below our $7.0M and consensus

Lexicon Pharmaceuticals Receives a Hold from Needham

In a report released today, Alan Carr from Needham maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares opened today at $13.53. Carr noted: “Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg